Nov.17,2025
FIMECS to Present at the Australian Ubiquitin Summit 2025
News release
Kanagawa, Japan, 14th November 2025 – FIMECS, Inc. (“FIMECS”), a private biotechnology company pioneering a new class of medicines through targeted protein degradation, today announced that Dr. Kanae Gamo, CSO has been invited to deliver an oral presentation at the Inaugural Australian Ubiquitin Summit 2025, taking place in Lorne, Victoria, Australia, from 20th – 23rd November 2025
Presentation Details:
Title: Accelerating TPD Discovery through RaPPIDSTM Platform: Unlocking the E3 Ligase Space
Presenter: Dr. Kanae Gamo, CSO
Time and Date: 4:10 pm – 4:45 pm, Saturday, November 22nd, 2025
In her invited presentation, Dr. Gamo will highlight FIMECS’ proprietary RaPPIDS™ platform, a high-throughput and phenotypic-first discovery system for targeted protein degradation. She will present the company’s latest advances in the discovery and application of novel E3 ligase binders, and how these innovations expand degrader design space and enable next-generation TPD drug discovery.
The Australian Ubiquitin Summit is a newly established international conference dedicated to the biology and therapeutic applications of ubiquitin signaling. The inaugural 2025 meeting brings together world-leading researchers and industry executives to discuss advances in ubiquitin biology, protein homeostasis, disease mechanisms, and next-generation modalities such as targeted protein degradation. The program features keynote lectures, invited talks, poster presentations, and a dedicated TPD-focused day, offering a comprehensive view of the rapidly evolving ubiquitin and protein degradation field.
More information: https://www.lorneubiquitin.org/
About FIMECS, Inc.
FIMECS, Inc. is a wholly-owned subsidiary of RaQualia Pharma (TSE:4579). The company is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. By integrating proprietary E3 ligase binders and the RaPPIDS™ platform, FIMECS can discover drug candidates that induce the degradation of disease-relevant proteins. This drug discovery platform enable the company to deliver innovative drugs to patients worldwide through both internal and collaboration projects. https://www.fimecs.com/eng/
# # #
FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
E-mail：info@fimecs.com